Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,030 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors.
Ouchi K, Takahashi S, Chikamatsu S, Ito S, Takahashi Y, Kawai S, Okita A, Kasahara Y, Okada Y, Imai H, Komine K, Saijo K, Takahashi M, Shirota H, Takahashi M, Gamoh M, Ishioka C. Ouchi K, et al. Among authors: kawai s. Int J Clin Oncol. 2018 Aug;23(4):790-798. doi: 10.1007/s10147-018-1261-z. Epub 2018 Mar 7. Int J Clin Oncol. 2018. PMID: 29511940 Free PMC article.
Phase II study of S-1 plus oxaliplatin 130 mg/m2 in Japanese patients with advanced gastric cancer.
Kito Y, Machida N, Kawai S, Hamauchi S, Tsushima T, Todaka A, Yokota T, Yamazaki K, Fukutomi A, Onozawa Y, Tsuji K, Doyama H, Haraguchi Y, Nakashima K, Kunieda K, Taku K, Mori K, Yasui H. Kito Y, et al. Among authors: kawai s. Int J Clin Oncol. 2018 Dec;23(6):1084-1089. doi: 10.1007/s10147-018-1308-1. Epub 2018 Jun 21. Int J Clin Oncol. 2018. PMID: 29931597 Clinical Trial.
Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Kawahira M, Yokota T, Hamauchi S, Kawai S, Yoshida Y, Onozawa Y, Tsushima T, Todaka A, Machida N, Yamazaki K, Fukutomi A, Yasui H. Kawahira M, et al. Among authors: kawai s. Int J Clin Oncol. 2018 Dec;23(6):1189-1195. doi: 10.1007/s10147-018-1306-3. Epub 2018 Jun 15. Int J Clin Oncol. 2018. PMID: 29948238
Comparison of enteral nutrition with total parenteral nutrition for patients with locally advanced unresectable esophageal cancer harboring dysphagia in definitive chemoradiotherapy.
Furuta M, Yokota T, Tsushima T, Todaka A, Machida N, Hamauchi S, Yamazaki K, Fukutomi A, Kawai S, Kawabata T, Onozawa Y, Yasui H. Furuta M, et al. Among authors: kawai s. Jpn J Clin Oncol. 2019 Oct 1;49(10):910-918. doi: 10.1093/jjco/hyz089. Jpn J Clin Oncol. 2019. PMID: 31219161
Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck.
Kimura H, Hamauchi S, Kawai S, Onozawa Y, Yasui H, Yamashita A, Ogawa H, Onoe T, Kamijo T, Iida Y, Onitsuka T, Yokota T. Kimura H, et al. Among authors: kawai s. Int J Clin Oncol. 2020 Feb;25(2):258-266. doi: 10.1007/s10147-019-01560-5. Epub 2019 Oct 16. Int J Clin Oncol. 2020. PMID: 31620932
Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203).
Takahashi M, Sakamoto Y, Otsuka K, Kanbe M, Ohori H, Shindo Y, Honda H, Saijo K, Ouchi K, Murakawa Y, Takahashi H, Kawai S, Tanaka Y, Yamaguchi T, Shimodaira H, Yoshioka T, Ishioka C. Takahashi M, et al. Among authors: kawai s. Tohoku J Exp Med. 2021 May;254(1):49-55. doi: 10.1620/tjem.254.49. Tohoku J Exp Med. 2021. PMID: 34053967 Free article. Clinical Trial.
Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.
Takahashi S, Ouchi K, Sakamoto Y, Mori T, Shimodaira H, Takahashi M, Ohori H, Kudo C, Takahashi Y, Imai H, Akiyama S, Takahashi M, Suto T, Murakawa Y, Oishi T, Isobe H, Okada Y, Kawai S, Yoshioka T, Sato T, Shindo Y, Sugiyama S, Komine K, Chiba N, Okita A, Yamaguchi T, Ishioka C. Takahashi S, et al. Among authors: kawai s. J Gastrointest Oncol. 2023 Apr 29;14(2):676-691. doi: 10.21037/jgo-22-862. Epub 2023 Mar 27. J Gastrointest Oncol. 2023. PMID: 37201044 Free PMC article.
2,030 results